Mirati Therapeutics, Inc. Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.

MRTX

Rang în acțiuni #4925
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Preț acțiune
$58.70
Ultima sincronizare: 2024-01-23
Capitalizare de piață
$2.98B
Schimbare (1 zi)
0.00%
Schimbare (1 an)
0.00%
Țară
US
Tranzacționează Mirati Therapeutics, Inc. (MRTX)

Categorie

Healthcare
Istoricul spliturilor pentru Mirati Therapeutics, Inc. (MRTX)
Acțiunea Mirati Therapeutics, Inc. (simbol: MRTX) a trecut printr-un total de 0 splituri.
Cel mai recent split a avut loc pe Oct 21, 2026.
O acțiune MRTX cumpărată înainte de Oct 21, 2026 este echivalentă astăzi cu 0 acțiuni MRTX.
Listă splituri acțiuni
An Split Multiplu Multiplu cumulativ
Nu sunt suficiente date pentru perioada selectată.
Splituri pentru companii similare sau competitori
Companie Număr total de splituri Multiplu cumulativ Țara
1 x2
US
0 -
US
1 x3
AU
0 -
NL
0 -
CH